

Complicaciones gastrointestinales de la diabetes

Referencias

1. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. *N Engl J Med.* 1993;329(14):977-986.
2. Bytzer P, Talley NJ, Leemon M, et al. Prevalence of gastrointestinal symptoms associated with diabetes mellitus: a population-based survey of 15,000 adults. *Arch Intern Med.* 2001;161(16):1989-1996.
3. Bytzer P, Talley NJ, Hammer J, Young LJ, Jones MP, Horowitz M. GI symptoms in diabetes mellitus are associated with both poor glycemic control and diabetic complications. *Am J Gastroenterol.* 2002;97(3):604-611.
4. Rayner CK, et al. Relationships of upper gastrointestinal motor and sensory function with glycemic control. *Diabetes Care.* 2001;24(2):371-381.
5. Ebert EC. Gastrointestinal complications of diabetes mellitus. *Dis Mon.* 2005;51(12):620-663.
6. Lluch I, Ascaso JF, Mora F, et al. Gastroesophageal reflux in diabetes mellitus. *Am J Gastroenterol.* 1999;94(4):919-924.
7. Camilleri M. Clinical practice. Diabetic gastroparesis [published correction appears in *N Engl J Med.* 2007;357(4):427]. *N Engl J Med.* 2007;356(8):820-829.
8. Yoshida MM, Schuffler MD, Sumi SM. There are no morphologic abnormalities of the gastric wall or abdominal vagus in patients with diabetic gastroparesis. *Gastroenterology.* 1988;94(4):907-914.
9. Ordög T, Takayama I, Cheung WK, Ward SM, Sanders KM. Remodeling of networks of interstitial cells of Cajal in a murine model of diabetic gastroparesis. *Diabetes.* 2000;49(10):1731-1739.
10. Parkman HP, Hasler WL, Fisher RS, et al. American Gastroenterological Association technical review on the diagnosis and treatment of gastroparesis. *Gastroenterology.* 2004;127(5):1592-1622.
11. Tougas G, Chen Y, Coates G, et al. Standardization of a simplified scintigraphic methodology for the assessment of gastric emptying in a multicenter setting. *Am J Gastroenterol.* 2000;95(1):78-86.
12. Quigley EM, Hasler W, Parkman HP. AGA technical review on nausea and vomiting. *Gastroenterology.* 2001;120(1):263-286.
13. Abell TL, Bernstein RK, Cutts T, et al. Treatment of gastroparesis: a multidisciplinary clinical review. *Neurogastroenterol Motil.* 2006;18(4):263-283.
14. Jebbink RJ, Samsom M, Bruijs PP, et al. Hyperglycemia induces abnormalities of gastric myoelectrical activity in patients with type 1 diabetes mellitus. *Gastroenterology.* 1994;107(5):1390-1397.
15. Bujanda L. The effects of alcohol consumption upon the gastrointestinal tract. *Am J Gastroenterol.* 2000;95(12):3374-3382.
16. Galligan JJ, Vanner S. Basic and clinical pharmacology of new motility promoting agents. *Neurogastroenterol Motil.* 2005;17(5):643-653.
17. Degen L, Matzinger D, Merz M, et al. Tegaserod, a 5-HT₄ receptor partial agonist, accelerates gastric emptying and gastrointestinal transit in healthy male subjects. *Aliment Pharmacol Ther.* 2001;15(11):1745-1751.
18. Anand C, Al-Juburi A, Familoni B, et al. Gastric electrical stimulation is safe and effective: a long-term study in patients with drug-refractory gastroparesis in three regional centers. *Digestion.* 2007;75(2-3):83-89.
19. Jones MP, Maganti K. A systematic review of surgical therapy for gastroparesis. *Am J Gastroenterol.* 2003;98(10):2122-2129.
20. Maganti K, et al. Oral erythromycin and symptomatic relief of gastroparesis: a systematic review. *Am J Gastroenterol.* 2003;98(2):259-263.
21. Virally-Monod M, Tielmans D, Kevorkian JP, et al. Chronic diarrhoea and diabetes mellitus: prevalence of small intestinal bacterial overgrowth. *Diabetes Metab.* 1998;24(6):530-536.
22. Maleki D, et al. Pilot study of pathophysiology of constipation among community diabetics. *Dig Dis Sci.* 1998;43(11):2373-2378.
23. Angulo P, et al. Nonalcoholic fatty liver disease. *N Engl J Med.* 2002;346(16):1221-1231.
24. American Gastroenterological Association. American Gastroenterological Association medical position statement: nonalcoholic fatty liver disease. *Gastroenterology.* 2002;123(5):1702-1704.
25. Adams LA, Sanderson S, Lindor KD, Angulo P. The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. *J Hepatol.* 2005;42(1):132-138.
26. Angelico F, Burattin M, Alessandri C, Del Ben M, Lirussi F. Drugs improving insulin resistance for non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis. *Cochrane Database Syst Rev.* 2007;(1):CD005166.
27. Basaranoglu M, et al. A controlled trial of gemfibrozil in the treatment of patients with nonalcoholic steatohepatitis. *J Hepatol.* 1999;31(2):384.
28. Zein CO, et al. Chronic hepatitis C and type II diabetes mellitus: a prospective cross-sectional study. *Am J Gastroenterol.* 2005;100(1):48-55.

29. Petit JM, et al. Risk factors for diabetes mellitus and early insulin resistance in chronic hepatitis C. *J Hepatol.* 2001;35(2):279-283.
30. Fabris P, et al. Insulin-dependent diabetes mellitus during alpha-interferon therapy for chronic viral hepatitis. *J Hepatol.* 1998;28(3):514-517.
31. Vidal J, Ferrer JP, Esmatjes E, et al. Diabetes mellitus in patients with liver cirrhosis. *Diabetes Res Clin Pract.* 1994;25(1):19-25.
32. Phelps G, Chapman I, Hall P, et al. Prevalence of genetic haemochromatosis in diabetic patients. *Lancet.* 1989;2(8657):233-234.